株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

AN2728(アトピー性皮膚炎):予測と市場分析

AN2728 (Atopic Dermatitis) - Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 292831
出版日 ページ情報 英文 69 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
AN2728(アトピー性皮膚炎):予測と市場分析 AN2728 (Atopic Dermatitis) - Forecast and Market Analysis to 2022
出版日: 2013年11月30日 ページ情報: 英文 69 Pages
概要

当レポートでは、Anacorが開発中のホウ素含有低分子、ホスホジエステラーゼ阻害剤、AN2728について調査分析し、アトピー性皮膚炎の概要と治療ガイドライン、競合情勢、製品情報、主要国の売上予測、売上情報などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 症状

第4章 疾病の管理

  • 診断
  • 治療の概要

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価

第6章 機会とアンメットニーズ

  • 概要
  • アンメットニーズ
  • アンメットニーズのギャップ分析
  • 機会

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望薬

第8章 AN2728

  • 概要
  • 効能
  • 安全性
  • 投与・処方
  • 潜在的な臨床的位置付け
  • 潜在的な商業的位置付け
  • 価格と償還
  • SWOT分析
  • 予測

第9章 付録

図表

目次
Product Code: GDHC297DFR

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

Anacor is developing AN2728, a boron-containing small molecule for the potential treatment of atopic dermatitis. AN2728 inhibits phosphodiesterase 4 (PDE4) and reduces the production of TNF-a, a precursor involved in the immune response and subsequent inflammatory process seen in atopic dermatitis.

Scope

  • Overview of Atopic Dermatitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on AN2728 including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for AN2728 for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, India and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of AN2728 performance
  • Obtain sales forecast for AN2728 from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, India and China)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis
  • 4.2. Treatment Overview

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Unmet Needs
    • 6.2.1. A Systemic Drug for Severe Recalcitrant Patients
    • 6.2.2. Tests that Stratify Patients and Allow for a Tailored Treatment Approach
    • 6.2.3. A Drug that Effectively Controls Patients' Pruritus
    • 6.2.4. Further Research into the Pathophysiology of Atopic Dermatitis
    • 6.2.5. A Drug that Induces Disease Remission
    • 6.2.6. Improved Quality of Life for Both Patients and their Carers
  • 6.3. Unmet Needs Gap Analysis
  • 6.4. Opportunities
    • 6.4.1. Increase Treatment Armamentarium for Severe Recalcitrant Patients
    • 6.4.2. Predictive Tests for Patient Stratification
    • 6.4.3. More Therapeutic Options that Address Patients' Pruritus

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. AN2728

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement

8.8. SWOT Analysis

  • 8.9. Forecast
    • 8.9.1. Phase II Pipeline Products

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Atopic Dermatitis Patients
    • 9.4.2. Percent Drug-treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic Erosion
    • 9.4.5. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Author
    • 9.7.2. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Symptoms of Atopic Dermatitis
  • Table 2: Treatment Guidelines for Atopic Dermatitis
  • Table 3: Most Prescribed Drugs for Atopic Dermatitis by Severity in the Global Markets, 2013
  • Table 4: Leading Treatments for Atopic Dermatitis, 2013
  • Table 5: Overall Unmet Needs in Atopic Dermatitis - Current Level of Attainment
  • Table 6: Clinical Unmet Needs in Atopic Dermatitis - Gap Analysis, 2013
  • Table 7: Late-Stage Atopic Dermatitis Pipeline, 2013
  • Table 8: Comparison of Therapeutic Classes in Development for Atopic Dermatitis, 2013
  • Table 9: Product Profile - AN2728
  • Table 10: Efficacy Results for AN2728 in Mild to Moderate Adolescent Atopic Dermatitis Patients (Day 29)
  • Table 11: AN2728 SWOT Analysis, 2013
  • Table 12: Global Sales Forecasts ($m) for AN2728, 2012-2022
  • Table 13: Phase II and Phase I Atopic Dermatitis Pipeline, 2013
  • Table 14: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Immunologic Pathway Involved in Healthy, Acute Atopic Dermatitis, and Chronic Atopic Dermatitis Skin
  • Figure 2: Flow Chart of the Diagnosis and Management of Atopic Dermatitis
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Atopic Dermatitis, 2012-2022
Back to Top